Page 3 - Rachel Eides News Today

ZUG, Switzerland and BOSTON, March 29, 2023 -- CRISPR Therapeutics , a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that... | March 29, 2023

ZUG, Switzerland and BOSTON, March 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases

Oral presentation of encore clinical data from Phase 3 clinical trials of exa-cel - Oral and poster presentations on quality-of-life impacts of sickle cell disease or transfusion-dependent beta-thalassemia

01.11.2022 - -Exagamglogene autotemcel (exa-cel), formerly known as CTX001 submission to the U.S. Food and Drug Administration (FDA) for rolling review expected to begin in November, with completion of the U.S. submission package expected in Q1 2023; EMA and ...

ZUG, Switzerland and BOSTON, Sept. 28, 2022 -- CRISPR Therapeutics , a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that... | September 28, 2022

Exa-cel will be submitted to the U.S. FDA for rolling review beginning in November, with completion of the U.S. submission package in Q1 2023 - EMA and MHRA submissions are on track for Q4 2022 - Exa-cel

Data from 75 patients with transfusion-dependent beta thalassemia or severe sickle cell disease with follow-up of up to 37.2 months continue to demonstrate that exa-cel has the potential to be

- Vertex announces three additional abstracts on the burden of beta thalassemia and sickle cell disease accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR

ZUG, Switzerland and CAMBRIDGE, Mass., May 12, 2022 -- CRISPR Therapeutics , a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today... | May 12, 2022

ZUG, Switzerland, and CAMBRIDGE, Mass., and SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company...